PBF-677 is under clinical development by Palo BioFarma and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PBF-677 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PBF-677 overview
PBF-677 is under development for the treatment of ulcerative colitis and eosinophilic esophagitis. The drug candidate is administered through oral route in the form of capsule. It acts by targeting adenosine A receptor (ADORA1) and adenosine A3 receptor (ADORA3). The drug candidate was also under development for IgA Nephropathy (Berger's Disease)and glaucoma.
Palo BioFarma overview
Palo BioFarma is a Spanish biotechnology company. The scientists with experience in drug discovery in several pharmaceutical companies and mission of the Palobiofarma is to discover new drugs based on the modulation of adenosine receptors. The company is headquartered Mataró, Barcelona, Spain.
For a complete picture of PBF-677’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
